Loading clinical trials...
Loading clinical trials...
An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
Conditions
Interventions
Ecopipam
Placebo
Locations
2
United States
H.J. Jinnah
Atlanta, Georgia, United States
Hospital Universitario La Paz
Madrid, Spain
Start Date
December 1, 2012
Primary Completion Date
December 1, 2013
Completion Date
December 1, 2014
Last Updated
April 22, 2024
NCT06225661
NCT07333014
NCT03143283
NCT00935753
NCT03035110
NCT02595164
Lead Sponsor
Emalex Biosciences Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions